Skip to content
Screener

Schering-Plough SGP Net Operating Loss Carryforwards

Net Operating Loss Carryforwards at other companies

HRO
HarrowHROW
$37.12M+34.2%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$176.1M+27.1%

Other financials

Income statement

See full
Operating income-$15.4M-108%
Net income-$13.8M-56.6%
EPS (diluted)-$0.69+82.6%

Balance sheet

See full
Cash & equivalents$238.9M+312%
Total debt$1.6M
Total equity$250.1M+463%
Total assets$258.4M

Cash flow

See full
Operating cash flow-$13.5M-65.2%
CapEx$676.0K+312%
Free cash flow-$14.2M-70.0%

Valuation

See full
Market cap$791.7M-5.2%
Enterprise value$554.41M

Returns & leverage

See full
Return on equity-34.3%
Debt / equity
Current ratio38×

Where this comes from

Reported directly by Schering-Plough in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwards.

The source filing: Schering-Plough’s 10-K, filed March 26, 2026. Open the filing →

Filed
Mar 26, 2026, 5:23 PM EDT
Fiscal year
FY2025
Accession
0001778922-26-000020

FAQ

What is Schering-Plough's net operating loss carryforwards?
Schering-Plough (SGP) reported net operating loss carryforwards of $4.97M in Q4 2025.
What does net operating loss carryforwards mean?
These are tax assets representing losses that can be used to reduce taxable income in future periods. They provide a potential future tax shield, improving cash flow by lowering future tax payments. Investors monitor these to estimate the duration and magnitude of potential tax savings.

Ask your AI about Schering-Plough's net operating loss carryforwards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude